866-997-4948(US-Canada Toll Free)

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 26 Pages

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017'; Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.

The report 'Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017' outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease which include indications Autoimmune Disorders, Breast Cancer, Cancer Pain, Head And Neck Cancer Squamous Cell Carcinoma, Liver Fibrosis, Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Neuropathic Pain, Pancreatic Cancer, Primary Biliary Cirrhosis and Severe Acute Respiratory Syndrome (SARS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)
- The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Overview 5
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Therapeutics Development 6
Products under Development by Stage of Development 6
Products under Development by Therapy Area 7
Products under Development by Indication 8
Products under Development by Companies 9
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Therapeutics Assessment 11
Assessment by Mechanism of Action 11
Assessment by Route of Administration 12
Assessment by Molecule Type 13
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Companies Involved in Therapeutics Development 14
Mateon Therapeutics Inc 14
Phelix Therapeutics LLC 14
Virobay Inc 14
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Drug Profiles 16
Drugs to Inhibit Cathepsin L for Coronaviridae Infections-Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
KGP-420-Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
KGP-94-Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
VBY-285-Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
VBY-825-Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Dormant Products 21
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Product Development Milestones 22
Featured News & Press Releases 22
Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017 22
Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference 22
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 23
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 23
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 25
Disclaimer 26

List of Tables
Number of Products under Development by Stage of Development, H2 2017 6
Number of Products under Development by Therapy Areas, H2 2017 7
Number of Products under Development by Indication, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Products under Development by Companies, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Stage and Route of Administration, H2 2017 12
Number of Products by Stage and Molecule Type, H2 2017 13
Pipeline by Mateon Therapeutics Inc, H2 2017 14
Pipeline by Phelix Therapeutics LLC, H2 2017 14
Pipeline by Virobay Inc, H2 2017 15
Dormant Projects, H2 2017 21

List of Figures
Number of Products under Development by Stage of Development, H2 2017 6
Number of Products under Development by Therapy Areas, H2 2017 7
Number of Products under Development by Top 10 Indications, H2 2017 8
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Stage and Route of Administration, H2 2017 12
Number of Products by Stage and Molecule Type, H2 2017 13

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *